|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Cardiac Surgery, Ziekenhuis Oost-Limburg – Campus St. Jan, Schiepse Bos 6, Genk 3600, Belgium
(Email: robert.dion@zol.be).
| The first 20% of the full text of this article appears below. |
The authors [1] conclude that intrinsic mitral valve (MV) pathology is frequently observed in hypertrophic cardiomyopathy (HCM) and that durable repair is feasible in only approximately half of the patients. I would add that this is only done by experienced surgeons, indeed, as a prosthetic valve has no systolic anterior motion (SAM) of the mitral coaptation line, and the authors have not been able to demonstrate a difference in survival between repair and replacement.
Their analysis identified 6 nonmutually exclusive groups, but why is a "long-leaflets group" different from the degenerative and myxomatous ones? Also, I hardly distinguished
Related Article
Ann. Thorac. Surg. 2008 85: 1527-1535.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |